https://www.live-feeds.com/feed/is-ultragenyx-stock-a-buy-after-gtx-102-flop-analysts-point-to-commercial-pipelineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/is-ultragenyx-stock-a-buy-after-gtx-102-flop-analysts-point-to-commercial-pipelinehttps://www.live-feeds.com/feed/is-ultragenyx-stock-a-buy-after-gtx-102-flop-analysts-point-to-commercial-pipeline#u57414Fri, 04 Sep 2026 22:51:35 +0000Ultragenyx shares crashed 44% to a record low after its GTX-102 drug failed a late-stage phase 3 trial for Angelman syndrome. The failure of the antisense oligonucleotide (ASO) triggered a market sell-off despite some investor optimism surrounding a separate Genglycos win. In response to the clinical setback, the company is planning significant expense reductions. Some analysts suggest the stock may still be a buy by focusing on the company's remaining commercial pipeline.Why it mattersAngelman syndrome is a rare disease. This trial failure removes a high-potential candidate from the comp